The UAB Comprehensive Diabetes Center (UCDC) and Diabetes Research Center (DRC) members and trainees will share their latest scientific findings at the world’s largest diabetes conference, the American Diabetes Association (ADA) 86th Scientific Sessions, June 5-8, at the Ernest N. Morial Convention Center in New Orleans.
Last year’s meeting in Chicago featured more than 2,000 original research presentations and 11,000 attendees, according to the ADA. This year, UAB faculty, staff, and trainees will showcase their work in a variety of symposiums, oral presentations, and poster presentations throughout the conference. Some will also participate in debates and as symposium and panel chairs.
See the list of UAB’s participation at ADA below and when and where you can find us!
UAB at ADA
Symposiums
Ananda Basu, M.D., Continuous Glucose Monitoring for Epidemiological Insights in Type 1/Type 2 Diabetes, Sat., June 6, 4:50 p.m. - 5:05 p.m., 217 (Level 2)
W. Timothy Garvey, M.D., Symposium Chair, Amylin as a Novel Diabetes and Obesity Therapy, Fri., June 5, 3:45 p.m. - 5:15 p.m., Great Hall A (Level 1)
W. Timothy Garvey, M.D., Long-Acting Amylins and the Pharmacotherapeutic Landscape of Obesity and Diabetes, Fri., June 5, 4:35 p.m. - 4:55 p.m. Great Hall A (Level 1)
W. Timothy Garvey, M.D., GLP-1 Receptor Agonist: Improved Fatty Liver and Cardiovascular Risk, Mon., June 8, 3:55 p.m. - 4:15 p.m., R05 (Level 2)
Carrie R. Howell, Ph.D., Symposium Chair, Advancing Diabetes Epidemiology with Real-World Data and AI, Sat., June 6, 4:30 p.m. - 6:00 p.m., 217 (Level 2)
Caroline Presley, M.D., MPH, Advancing the Diabetic Eye Disease Care Continuum: Screening, Referral Pathways, Specialty Care, and Quality Outcomes, Fri., June 5, 4:05 p.m. - 4:25 p.m., Great Hall B (Level 1)
Oral Presentations
SeongHo Jo, Ph.D., Junqin Chen, Ph.D., Gu Jing, Ph.D., Anath Shalev, M.D., TIX100 Protects Against Weight Rebound After Semaglutide Discontinuation, Mon., June 8, 1:30 p.m. - 1:45 p.m., 343 (Level 3)
Erika Zagallo, M.S., Michele Schiavon, Ph.D., FNU Ruchi, M.D., C. Dalla Man, Ph.D., Rita Basu, M.D., Ananda Basu, M.D., Glucose and Not Insulin Appears to be the Main Regulator of Glucagon Secretion in Healthy Individuals, Mon., June 8, 1:45 p.m. - 2:00 p.m., R07 (Level 2)
Poster Presentations
Jacopo Bonet, Ph.D., Michele Schiavon, Ph.D., Ananda Basu, M.D., C. Dalla Man, Ph.D., Rita Basu, M.D., Characterizing the Diurnal Variability of Insulin Sensitivity and beta-cell responsivity in People with Type 2 diabetes, Sun., June 7, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-2467
Sean Brown, M.D., Fernando Bril, M.D., Einer Arevalo-Rios, M.D., Liming Pei, Ph.D., G. Londono, Rita Basu, M.D., Ananda Basu, M.D., Mary Elizabeth Patti, M.D., Glycemic Response to Glucagon in Patients with Post-Bariatric Hypoglycemia, Sat., June 6, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-1368
Sai Sumedha Bobba, BS, MBA, Implementation of FIB-4 Alerts in EHRs to Increase Screening for Liver Disease, Sun., June 7, 12:30 p.m. - 1:30 p.m. Poster Halls D-E, P-2930
KaLia S. Burnette, Investigating Cyclophosphamide-Induced Diabetes to Study Autoimmune-Driven Graft Rejection in NOD Mice, Sat., June 6, 12:30p.m. - 1:30 p.m., Poster Halls D-E, P-2421
Macie M Craft, BSN, MSN, A Quality Improvement Initiative to Increase Screening for Diabetic Eye Disease, Sat., June 6, 12:30p.m. - 1:30p.m., Poster Halls D-E, P-1441
W. Timothy Garvey, M.D., Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1, Sun., June 7, 12:30 p.m. - 1:30 p.m., Poster Hall (Halls D-E), P-3083
Andrew Hardaway, Ph.D., Central Amygdala Glucagon-Like Peptide 1 Receptor Neurons Integrate Endogenous GLP-1 and Encode Consummatory Valence through Diverse Outputs, Sun., June 7, 12:30p.m. - 1:30p.m., Poster Halls D-E, P-3051
Gu Jing, Ph.D., Guanlan Xu, Ph.D., Anath Shalev, M.D., The Good and the Bad of Verapamil vs. Other Calcium Channel Blockers in the Context of Diabetes, Sun., June 7, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-1804
Seung-Yup Lee, Ph.D., Social Vulnerability Moderates the Protective Effect of Insulin Initiation on ED Return: A Mixed-Methods Study, Sun., June 7, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-2913
Dawn Matthies, Ph.D., The Artificial Intelligence Ready and Exploratory Atlas for Diabetes Insights (AI-READI) Dataset: Purpose, Design, Availability, and Use, Sat., June 6, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-2301
Kelly Nicole Brunson Palmer, Ph.D., MS, Community-Informed Implementation Strategies for Salon-Based Diabetes Risk Screening, Sat., June 6, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-1635
Kelly Nicole Brunson Palmer, Ph.D., MS, Feasibility of a Salon-Based Diabetes Risk Screening and Prevention Program Referral Intervention, Mon., June 8, 12:30p.m. - 1:30p.m., Poster Halls D-E, P-1474
Marian Leah Yurchishin, MS, Gower Lab, Associations between Fasting Lactate, Beta-Cell Function, and Diet Are Differentially Impacted by Race, Sun., June 7, 12:30 p.m. - 1:30 p.m., Poster Halls D-E, P-3038
Aseel El Zein, Ph.D., RDN, Patterns of Engagement and Alert Burden in Remote Patient Monitoring for Uncontrolled Type 2 Diabetes: A Pragmatic Multisite Trial Sat., June 6, 12:30p.m. - 1:30p.m., Poster Halls D-E, P-1948
Panel Discussions
Ashley Battarbee, M.D., MSCR, Panel Chair, Make New Friends, but Keep the Old? Updates on Insulin Therapy in Pregnancy, Fri., June 5, 3:45 p.m. - 5:15 p.m., Hall E-2 (Level 1)
Debates
Kirk Habegger, Ph.D., (Friend and Rebuttal Debate), The Glucagon Agonism Paradox: Friend or Foe in the Fight against Hyperglycemia? Sun., June 7, 3:15 p.m. - 4:15 p.m., La Nouvelle Orleans C (Level 2)
Be sure to add the above talks and poster presentations to your program scheduler to support fellow colleagues. If you have an upcoming presentation you would like to share, email
This information was sourced from the 2026 ADA Scientific Sessions Online Planner. Date and times are subject to change.